Maxim Group Downgrades Mast Therapeutics (MSTX) to Hold Following Vepoloxamer Phase 3 Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Laidlaw Downgrades Mast Therapeutics (MSTX) to Neutral
September 21, 2016 11:46 AM EDTLaidlaw downgraded Mast Therapeutics (NYSE: MSTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Mast Therapeutics click here. For more ratings news on Mast Therapeutics click here.
Shares of Mast Therapeutics closed at $0.59 yesterday.
... MoreMast Therapeutics (MSTX) Reports Vepoloxamer Phase 3 in Sickle Cell Missed Primary Endpoint
September 20, 2016 5:02 PM EDTMast Therapeutics, Inc. (NYSE: MSTX) reported top-line results from EPIC, a Phase 3 clinical study of its investigational new drug vepoloxamer (also known as MST-188) for the treatment of individuals with sickle cell disease experiencing vaso-occlusive crisis (VOC). The study did not meet its primary efficacy endpoint of demonstrating a statistically significant reduction in the mean duration of VOC (82 hours in the vepoloxamer group compared to 78 hours in the placebo group in the intent-to-treat population (p=0.09)). There were no statistically significant differences... More
